Done Deal: LEO Pharma Closes Deal for BI’s Spesolimab (Spevigo)

October 2, 2025

Gene Therapy Skin Grafts and Gel Hope Spell Hope for EB Patients

June 24, 2025

Phase 2 Data: Rigosertib (Traws Pharma) Shows 80% Response Rate in RDEB SCC

June 3, 2025

DEBRA Research, Dermaliq Team Up to Advance Cutaneous Drug Delivery for EB

May 28, 2025

U.S. FDA Approves ZEVASKYN, the First and Only FDA-approved Product for Recessive Dystrophic Epidermolysis Bullosa

April 29, 2025

EMA’s CHMP Recommends Krystal’s Vyjuvek for Dystrophic Epidermolysis Bullosa

March 3, 2025

U.S. FDA Approves First Treatment for Cerebrotendinous Xanthomatosis

February 23, 2025

Tampere University, Theravia Partner to Advance New EB Drug

February 19, 2025

Clinical Trial Update: First Patient Dosed in Phase 1/2a Trial of AGLE-102 in DEB

August 14, 2024

Rare Skin Disease Treatment Update: Transplanting Genetically Healthy Skin to Inflamed Areas May Help Treat EI and IWC

June 10, 2024

Epidermolysis Bullosa: A Clinical Review and Update

May 21, 2024

CBD Cream Shows Promise in EB

May 21, 2024